CY1107452T1 - Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων - Google Patents

Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων

Info

Publication number
CY1107452T1
CY1107452T1 CY20081100471T CY081100471T CY1107452T1 CY 1107452 T1 CY1107452 T1 CY 1107452T1 CY 20081100471 T CY20081100471 T CY 20081100471T CY 081100471 T CY081100471 T CY 081100471T CY 1107452 T1 CY1107452 T1 CY 1107452T1
Authority
CY
Cyprus
Prior art keywords
restless leg
leg syndrome
treatment
administration
transmitteral
Prior art date
Application number
CY20081100471T
Other languages
English (en)
Inventor
Thomas Lauterbach
Erwin Schollmayer
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29285132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107452(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of CY1107452T1 publication Critical patent/CY1107452T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Η εφεύρεση αφορά μια περιέχουσα ροτιγοτίνη διαδερμική φαρμακευτική σύνθεση για την αποτελεσματική θεραπεία του συνδρόμου ανήσυχων ποδιών (RLS), ιδιαιτέρως σε μορφή ενός διαδερμικού θεραπευτικού συστήματος (TDS) με βάση ακρυλικό ή σιλικόνη με επιφάνεια από 2,5 έως 20 cm2, το οποίο περιέχει 1,125 έως 9,0 mg/cm2 ροτιγοτίνης ως δραστικό συστατικό κατά του συνδρόμου ανήσυχων ποδιών, το οποίο σύμφωνα με την κλίμακα αξιολόγησης της διεθνούς ομάδας μελέτης του συνδρόμου ανήσυχων ποδιών (IRLSSG) επιφέρει βελτίωση της κατάστασης ασθενών που πάσχουν από το σύνδρομο ανήσυχων ποδιών σε σύγκριση με μια εικονική θεραπεία κατά 2 μονάδες ή περισσότερο, μετά από χορήγηση για χρονικό διάστημα τουλάχιστον 8 ημερών.
CY20081100471T 2002-05-06 2008-05-02 Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων CY1107452T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10220230A DE10220230A1 (de) 2002-05-06 2002-05-06 Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
EP03727432A EP1501499B1 (de) 2002-05-06 2003-05-05 Transepikutane darreichungsform zur behandlung des restless leg syndroms

Publications (1)

Publication Number Publication Date
CY1107452T1 true CY1107452T1 (el) 2012-12-19

Family

ID=29285132

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100471T CY1107452T1 (el) 2002-05-06 2008-05-02 Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων

Country Status (24)

Country Link
EP (1) EP1501499B1 (el)
JP (2) JP5253707B2 (el)
KR (1) KR20040104697A (el)
CN (1) CN100396281C (el)
AT (1) ATE387912T1 (el)
AU (1) AU2003233233B2 (el)
BR (1) BR0309837A (el)
CA (2) CA2483120C (el)
CY (1) CY1107452T1 (el)
DE (2) DE10220230A1 (el)
DK (1) DK1501499T3 (el)
ES (1) ES2301795T3 (el)
HK (1) HK1072541A1 (el)
IL (2) IL164861A0 (el)
MX (1) MXPA04010687A (el)
NO (1) NO333619B1 (el)
NZ (1) NZ536533A (el)
PL (1) PL218549B1 (el)
PT (1) PT1501499E (el)
RU (1) RU2301063C9 (el)
SI (1) SI1501499T1 (el)
UA (1) UA81625C2 (el)
WO (1) WO2003092677A1 (el)
ZA (1) ZA200408862B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
AU2006343077B2 (en) * 2006-05-08 2012-11-08 Teikoku Seiyaku Co., Ltd. Tansdermally absorbable preparation comprising anti-dementia agent
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MX2010005925A (es) 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
EP2255809B1 (en) * 2008-02-27 2017-08-23 Hisamitsu Pharmaceutical Co., Inc. Medicated patch
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EA025584B1 (ru) * 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
US8729306B2 (en) 2010-02-05 2014-05-20 Ucb Pharma Gmbh Process for the preparation of nitrogen substituted aminotetralins derivatives
KR20130122721A (ko) 2010-06-25 2013-11-08 유씨비 파르마 게엠베하 질소 치환된 （ｓ）―５―알콕시―２―아미노테트랄린 유도체의 분리 방법
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
KR101558043B1 (ko) * 2012-07-06 2015-10-07 에스케이케미칼주식회사 로티고틴 함유 경피흡수제제
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
JPWO2015129527A1 (ja) 2014-02-27 2017-03-30 株式会社 メドレックス プラミペキソールを含有する神経変性疾患の治療用貼付剤
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CN113950356A (zh) 2019-06-14 2022-01-18 久光制药株式会社 含罗替戈汀的贴附剂
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
PT1256339E (pt) * 2001-05-08 2004-02-27 Lohmann Therapie Syst Lts Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.

Also Published As

Publication number Publication date
CA2787384A1 (en) 2003-11-13
ATE387912T1 (de) 2008-03-15
PL373276A1 (en) 2005-08-22
KR20040104697A (ko) 2004-12-10
DE50309318D1 (de) 2008-04-17
SI1501499T1 (sl) 2008-06-30
BR0309837A (pt) 2005-03-01
CA2483120C (en) 2013-07-16
IL164861A (en) 2011-06-30
JP2010159302A (ja) 2010-07-22
JP2005528413A (ja) 2005-09-22
ES2301795T3 (es) 2008-07-01
RU2004131866A (ru) 2005-06-10
EP1501499A1 (de) 2005-02-02
NO333619B1 (no) 2013-07-22
DK1501499T3 (da) 2008-06-23
ZA200408862B (en) 2005-09-28
RU2301063C9 (ru) 2007-11-27
AU2003233233B2 (en) 2008-03-06
AU2003233233A1 (en) 2003-11-17
NZ536533A (en) 2010-02-26
WO2003092677A1 (de) 2003-11-13
JP5253707B2 (ja) 2013-07-31
UA81625C2 (ru) 2008-01-25
RU2301063C2 (ru) 2007-06-20
CN1665497A (zh) 2005-09-07
DE10220230A1 (de) 2003-11-27
CA2483120A1 (en) 2003-11-13
NO20045240L (no) 2004-11-30
CN100396281C (zh) 2008-06-25
IL164861A0 (en) 2005-12-18
MXPA04010687A (es) 2005-06-08
EP1501499B1 (de) 2008-03-05
HK1072541A1 (en) 2005-09-02
PT1501499E (pt) 2008-05-20
PL218549B1 (pl) 2014-12-31

Similar Documents

Publication Publication Date Title
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
DK1392256T3 (da) Forbedret transdermalt behandlingssystem til behandling af Parkinsons sygdom
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
DK1587506T3 (da) Administration af capsaicinoider
DK1898876T3 (da) Mucoadhæsive xyloglucanholdige fprmuleringer anvendelige i medicinske anordninger og i farmaceutiske former
RU2003133217A (ru) Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
DE602005024571D1 (de) Opioide zur behandlung von ruhelosigkeit in den unteren gliedmassen
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
DK1154795T3 (da) Middel til behandling af diagnosticering af restless legs syndrom
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
NO20024673D0 (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
SE0102887D0 (sv) New formulation
DE602004029993D1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
DK1328273T3 (da) Anordning og fremgangsmåder til transdermal indgivelse af felodipin
ATE543495T1 (de) Pharmazeutische zusammensetzung mit einer ruthenium-oxalato-verbindung und anwendungsverfahren dafür